Biopharmaceutical Fermentation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Biopharmaceutical Fermentation Market Analysis

The Biopharmaceutical Fermentation Market size is estimated at USD 27.70 billion in 2024, and is expected to reach USD 44.27 billion by 2029, growing at a CAGR of 9.83% during the forecast period (2024-2029).

COVID-19 has impacted the growth of the biopharmaceutical fermentation market. The pandemic resulted in an unprecedented demand for enzymes essential for innovative point-of-care diagnostic kits and mRNA vaccines. For instance, according to the report published by MassBio, in December 2022, it has been observed that the COVID-19 epidemic has increased and reinforced the demand for complex fermentation products in the pharmaceutical and biotechnology industries. Globally, companies and populations benefited from crucial supplies of enzymes produced by fermentation. Moreover, the production of new biologic drugs during the pandemic period for the treatment of COVID-19 infection increased which has impacted the market growth. For instance, in December 2021, Samsung Biologics and AstraZeneca expanded a strategic biopharmaceutical production partnership to include therapies for Covid-19. However, the emergence of a new variety of viruses accelerates vaccine production which involves the fermentation step. For instance, in July 2022, CEPI funded USD 30 million to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trials. Thus, with such initiatives, the studied market is expected to grow and regain its full potential in the coming years.

Factors such as the increasing demand for biotech-based drugs and rising research and development activities to produce novel biological drugs are boosting market growth. For instance, according to the 2021 annual report of AbbVie, Humira is one of the top-selling biotechnology drugs in the world which accounted for net revenues of USD 20.7 billion and approximately 37% of AbbVie's total net revenues in 2021. Globally, Humira sales increased by 4% in 2021 compared with the previous year. Similarly, as per the 2021 annual report of Merck & Co, the sales of Keytruda, one of the major biotech-based drugs of the company, grew by 20% to USD 17.2 Billion, compared to USD 14.9 Billion in the year 2020. Thus, the increasing sales of biotech-based drugs in the market indicates the increasing demand for these drugs in the market which in turn is anticipated to fuel the market growth over the forecast period.

Furthermore, the rising company focus on developing novel biological drugs is also expected to fuel the demand for fermentation services and products which is anticipated to propel the market growth. For instance, in November 2022, Eikonoklastes Therapeutics, a preclinical biotech company, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization entered a manufacturing partnership that will advance Eikonoklastes' AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS). Also, in August 2022, Sanofi and Innovent Biologics entered a strategic collaboration to accelerate the development of two biologic oncology medicines (tusamitamab ravtansine, SAR444245) and expand their presence in China.

Therefore, owing to the factors, such as the rising company activities and increasing demand for biotech-based drugs, the studied market is anticipated to grow over the forecast period. However, the high cost of biopharmaceutical fermentation and installation is likely to impede the growth of the biopharmaceutical fermentation market over the forecast period.

Biopharmaceutical Fermentation Market Trends

This section covers the major market trends shaping the Biopharmaceutical Fermentation Market according to our research experts:

Chromatography Segment Expects to Register a Significant CAGR Over the Forecast Period

Biopharmaceutical Fermentation Industry Segmentation

As per the scope of the report, biopharmaceutical fermentation systems or bioprocessing can be defined as the process of incubating microorganisms within an enclosed tank, under controlled conditions of aeration, agitation, temperature, and pH. Upstream bioprocessing deals with the use of living cells to obtain desired products, where the process starts from early cell separation, and cultivation to cell culture expansion to harvest. Downstream processing includes the recovery and purification of biological products. The downstream is an essential part of the manufacturing of vaccines, antibodies, antibiotics, and hormones, such as insulin and human growth hormone. The Biopharmaceutical Fermentation Market is Segmented by Product Type (Upstream products (Bioreactors/Fermenters, Bioprocess Analyzers, Process Monitoring Systems, and Other Upstream Products), and Downstream Products (Filtration and Separation, Chromatography, Consumables and Accessories, and Other Downstream Products), Applications (Antibiotics, Recombinant Proteins, Probiotics, and Other Applications), End User (Biopharmaceutical Industries, Contract Research Organizations (CROs) and CDMOs, Academic Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.